Novartis builds IL-17 franchise with Ensemble's small molecule
This article was originally published in Scrip
Executive Summary
Novartis is building on its leading position in the development of antibody therapeutics against the inflammatory and autoimmune disease target interleukin 17 (IL-17) with a partnership to advance an oral small molecule IL-17 antagonist from Ensemble Therapeutics.